Coordinatore | DOUGLAS CONNECT
Organization address
address: Baermeggenweg 14 contact info |
Nazionalità Coordinatore | Switzerland [CH] |
Totale costo | 3˙775˙680 € |
EC contributo | 2˙975˙360 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-A |
Funding Scheme | CP-FP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-09-01 - 2011-08-31 |
# | ||||
---|---|---|---|---|
1 |
DOUGLAS CONNECT
Organization address
address: Baermeggenweg 14 contact info |
CH (ZEININGEN) | coordinator | 0.00 |
2 |
ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Organization address
address: FAHNENBERGPLATZ contact info |
DE (FREIBURG) | participant | 0.00 |
3 |
DAVID ANTHONY GALLAGHER
Organization address
address: "Park Mews, Park Road 3" contact info |
UK (CONGRESBURY) | participant | 0.00 |
4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 0.00 |
5 |
HELMA CHRISTOPH
Organization address
address: TALSTRASSE 20 contact info |
DE (FREIBURG) | participant | 0.00 |
6 |
IDEACONSULT LIMITED LIABILITY COMPANY
Organization address
address: ANGEL KANCHEV 4 contact info |
BG (SOFIA) | participant | 0.00 |
7 |
INSTITUTE OF BIOMEDICAL CHEMISTRY - RUSSIAN ACADEMY OF SCIENCES
Organization address
address: POGODINSKAYA STREET 10 contact info |
RU (MOSKVA) | participant | 0.00 |
8 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 0.00 |
9 |
NATIONAL TECHNICAL UNIVERSITY OF ATHENS - NTUA
Organization address
address: HEROON POLYTECHNIOU 9 ZOGRAPHOU CAMPUS contact info |
EL (ATHINA) | participant | 0.00 |
10 |
SEASCAPE LEARNING CO PRIVATE LTD
Organization address
address: "DOUBLE STOREY, NEW RAJINDER NGR 271" contact info |
IN (NEW DELHI) | participant | 0.00 |
11 |
TECHNISCHE UNIVERSITAET MUENCHEN
Organization address
address: Arcisstrasse 21 contact info |
DE (MUENCHEN) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The goal of the OpenTox project is to develop a predictive toxicology framework with a unified access to toxicological data, (Q)SAR models and supporting information. It will provide tools for the integration of data from various sources (public and confidential), for the generation and validation of (Q)SAR models, libraries for the development and integration of new (Q)SAR algorithms, and validation routines. OpenTox will attract toxicological experts without (Q)SAR expertise as well as model and algorithm developers. It will move beyond existing attempts to solve individual research issues, by providing a flexible and user friendly framework that integrates existing solutions and new developments. OpenTox will be relevant for REACH as it gives risk assessors simple access to experimental data, (Q)SAR models and toxicological information that adheres to European and international regulatory requirements. OpenTox will be published as an open source project to allow a critical evaluation of its algorithms, to promote dissemination, and to attract external developers. Facilities for the inclusion of confidential in-house data and for accessing commercial prediction systems will be included. OpenTox will contain high-quality data and (Q)SAR models for chronic, genotoxic and carcinogenic effects. These are the endpoints with the greatest potential to reduce animal testing. The impact of OpenTox will however go beyond REACH and long-term effects, because it will be straightforward to create models for other endpoints (e.g,. sensitisation, liver-toxicity, cardio-toxicity, ecotoxicity). The proposed framework will support the development of new (Q)SAR models and algorithms by automating routine tasks, providing a testing and validation environment and allowing the easy addition of new data. For this reason we expect, that OpenTox will lead to (Q)SAR models for further toxic endpoints and generally improve the acceptance and reliability of (Q)SAR models.'
"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes"
Read More